4 Healthcare Stock Stories to Kick Off the Week

Cellgene Corporation (NASDAQ:CELG): Closing price $100.02

Celgene said Friday that its Pomalyst brand therapy (pomalidomide) for patients suffering from multiple myeloma who have received a minimum of two prior therapies that included lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy, has been approved by the FDA.